Skip to content
OmniaBio Full Color Logo

Learn more about our CDMO facilities

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
  • Contact
OmniaBio Full Color Logo

Learn more about our CDMO facilities

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
  • Contact

Technical Poster

BROWSE ALL
May 3, 2024 | OmniaBio |
Poster

Key Analytical Assays for Characterization of CAR-T Products

Download Now
Download Now
Originally presented at the Cell Therapy Analytical Development Summit 2023, this poster shares data demonstrating our comprehensive analytics, which is essential to any cell therapy candidate. It showcases our recent advances in lentiviral infectious titer and VCN via ddPCR, CAR-T immunophenotyping release testing, and customized potency assay development, overviewing a robust and customizable platform to drive forward improved CAR-T cell therapies.

Since comprehensive CAR-T cell therapy production analytics are required for effective production and release testing, precise, repeatable, and customizable measurements are of utmost importance.

Submit your information to download the poster and learn how our in-house developed assays, each customizable to CARs of interest, can dramatically improve the characterization of CAR-T cell functionality and bring your cell therapy one step closer to reality.

About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.

Related Content
Loading...
Infographic preview
Poster
Manufacturing of CD19 CAR-T Cells Infographic
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
Image of poster
Poster
Flexible, Cost-Effective Manufacturing of CD19- CAR-T Cells Using the G-Rex® System
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
Image of poster
Poster
Closed, Automated Manufacturing of CD19- CAR-T Cells Using Cocoon® Platform and Gibco™ CTS™ Rotea™ for Harvest
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
Image of poster
Poster
High Throughput Screening of Lipid Nanoparticles for Enhanced Drug Delivery to Immune Cells
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
1 2 3 Next »
OmniaBio Footer Logo in Full Color

© 2025 OmniaBio   |   Privacy Policy

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
Contact Us
Scroll to Top